FindTrial
Sign In

Applications of ctDNA enrichment combined sanger sequencing technology and ctBEST technology in early screening of Lung Cancer

Applications of ctDNA enrichment combined sanger sequencing technology and ctBEST technology in early screening of Lung Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17012443
Enrollment
Unknown
Registered
2017-08-22
Start date
2017-10-01
Completion date
Unknown
Last updated
2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

sites&#32
included&#32
Gold Standard:This research adopts the ddPCR technology test results as the gold standard.
Index test:This&#32
research&#32
mainly&#32
detecting&#32
the&#32
mutation&#32
frequency&#32
of&#32
EGFR&#32
gene&#32
and&#32
Kras&#32
gene.&#32
The&#32
EGFR(del15)?EGFR(del18)?EGFR(L858R)and&#32
mutations&#32

Sponsors

The First People's Hospital of Chenzhou
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The permanent population of institutions and institutions; 2. Over 55 years of age; 3. The package includes people with a CT scan; 4. The CT results visible nodule (> 6 mm to 8 mm or less); 5. Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Exclude the patients received tumor treatment, such as chemotherapy, radiotherapy and surgery 2. Eliminate imaging results indicate except lung nodules.

Design outcomes

Primary

MeasureTime frame
frequency of gene mutation;—

Countries

China

Contacts

Public ContactLuo Dixian

The First People's Hospital of Chenzhou

luodixian_2@163.com+86 15273502335

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026